These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3865002)

  • 1. [High-dose cytosine arabinoside administration in the treatment of refractory leukemia].
    Yoshida M; Furukawa Y; Akashi M; Komatsu N; Takeda K; Muroi K; Ikeda K; Ohsaka A; Ohta M; Suda K
    Rinsho Ketsueki; 1985 Aug; 26(8):1258-64. PubMed ID: 3865002
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma].
    Shimazaki C; Fujita N; Nakanishi S; Nishio A; Haruyama H; Nakagawa M; Ijichi H
    Gan To Kagaku Ryoho; 1985 Nov; 12(11):2202-7. PubMed ID: 3864396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
    Kawano F; Tejima Y; Tajima H; Lee SY; Shiozaki A; Nakai R; Chyosa M; Sawada T; Maeda Y; Mizokuni T
    Rinsho Ketsueki; 1986 Mar; 27(3):315-20. PubMed ID: 3461178
    [No Abstract]   [Full Text] [Related]  

  • 4. [High-dose cytosine arabinoside therapy in refractory acute leukemia].
    Yorimitsu S; Takahashi I; Kitazima K; Kimura I; Hara M; Tokuda M
    Rinsho Ketsueki; 1984 Dec; 25(12):1941-6. PubMed ID: 6533329
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cytosine-arabinoside in the treatment of acute leukemias].
    Böhnel J; Gingold N; Hermansky F; Pawlowski M; Stacher A
    Wien Med Wochenschr; 1972 Apr; 122(15):203-7. PubMed ID: 4527321
    [No Abstract]   [Full Text] [Related]  

  • 6. [High dose cytosine arabinoside (HDCA) in children with refractory leukemia or malignant lymphoma (3 g/m2 vs 1.5 g/m2)].
    Yumura K; Kawa K; Ishihara S; Hara J; Doi S; Tomita K; Yabuuchi H
    Rinsho Ketsueki; 1985 Dec; 26(12):1979-85. PubMed ID: 3834163
    [No Abstract]   [Full Text] [Related]  

  • 7. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
    Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
    Cancer; 1997 Jan; 79(1):59-68. PubMed ID: 8988727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
    Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
    J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract]   [Full Text] [Related]  

  • 10. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
    Esumi N; Todo S; Arakawa S; Imashuku S
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia.
    Willemze R; Fibbe WE; Zwaan FE
    Neth J Med; 1983; 26(8):215-9. PubMed ID: 6580554
    [No Abstract]   [Full Text] [Related]  

  • 12. [High doses of cytosine arabinoside in the treatment of refractory leukemia].
    Klener P; Háber J; Kolesková E
    Sb Lek; 1987 Sep; 89(8-9):271-5. PubMed ID: 3478794
    [No Abstract]   [Full Text] [Related]  

  • 13. [High-dose cytosine arabinoside in acute leukemia: a cooperative study].
    Urabe A; Takaku F; Mizoguchi H; Yamada O; Wakabayashi Y; Miura Y; Sakamoto S; Yoshida M; Miwa S; Asano S
    Rinsho Ketsueki; 1985 Feb; 26(2):184-8. PubMed ID: 3894715
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of atypical leukemia].
    Mochizuki T; Sawada H; Okazaki T; Tashima M; Uchino H
    Gan To Kagaku Ryoho; 1986 May; 13(5):1816-22. PubMed ID: 3707144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Low-dose cytosine arabinoside (Ara-C) continuous infusion regimen for atypical nonlymphocytic leukemia--clinical study of the remission mechanism by serial chromosomal findings, colony formation and plasma Ara-C concentration].
    Tagawa M; Tomonaga M; Shibata J; Nishino K; Nonaka H; Ikeda S; Suzuyama J; Amenomori T; Matuo T; Kuriyama K
    Rinsho Ketsueki; 1984 Oct; 25(10):1606-17. PubMed ID: 6520937
    [No Abstract]   [Full Text] [Related]  

  • 16. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
    Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P
    J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864
    [No Abstract]   [Full Text] [Related]  

  • 18. [A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
    Miyawaki S; Mizoguchi H; Tomonaga M; Kanamaru A; Tsukagoshi S; Nakamura T; Ohashi Y; Yoshida S; Ohno R
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2229-42. PubMed ID: 9881080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies.
    Takubo T; Tani Y; Kubota Y; Oguma S; Ueda T; Nakamura H; Shibata H; Masaoka T
    Nihon Gan Chiryo Gakkai Shi; 1984 Feb; 19(1):1-7. PubMed ID: 6597236
    [No Abstract]   [Full Text] [Related]  

  • 20. [Complete remission achieved by high dose cytosine arabinoside therapy in the 4th relapse of AML].
    Sai M; Naganuma Y; Aoki I; Toyama K
    Rinsho Ketsueki; 1986 Jun; 27(6):952-5. PubMed ID: 3463813
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.